Edwards Lifesciences Co. (NYSE:EW) Receives Consensus Rating of “Hold” from Brokerages

Shares of Edwards Lifesciences Co. (NYSE:EW) have been assigned an average recommendation of “Hold” from the twenty-five brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $79.95.

A number of research analysts have recently weighed in on EW shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. The Goldman Sachs Group lifted their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Evercore ISI reduced their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research note on Wednesday, February 12th. Barclays lifted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Finally, Truist Financial reiterated a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $70.90 on Tuesday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12-month low of $58.93 and a 12-month high of $95.73. The firm has a market capitalization of $41.68 billion, a price-to-earnings ratio of 10.17, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The firm has a 50 day moving average of $71.49 and a 200 day moving average of $70.52.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, research analysts anticipate that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total value of $797,287.50. Following the sale, the chief financial officer now owns 30,387 shares of the company’s stock, valued at approximately $2,153,526.69. This represents a 27.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 400 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the sale, the vice president now owns 22,588 shares of the company’s stock, valued at $1,569,414.24. This trade represents a 1.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,553 shares of company stock worth $4,513,064 over the last ninety days. Company insiders own 1.29% of the company’s stock.

Institutional Trading of Edwards Lifesciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EW. Crowley Wealth Management Inc. purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth approximately $26,000. Vega Investment Solutions purchased a new stake in Edwards Lifesciences in the fourth quarter worth $27,000. Millstone Evans Group LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $30,000. Finally, FSA Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the third quarter valued at $30,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.